Overview
- The Phase 3 study published over the weekend reported 24‑month overall survival of 64.7% with ivonescimab plus chemotherapy versus 48.6% with tislelizumab plus chemotherapy and an approximately 34% reduction in the risk of death.
- Summit and partner Akeso also presented Phase 2 AK112‑206 colorectal data showing stronger, dose-dependent durability at 20 mg/kg, with a 9‑month duration-of-response landmark of 79.1% versus 41.5% at 10 mg/kg and a 9‑month PFS landmark of 76.1% for 20 mg/kg.
- Akeso sponsored the China Phase 3 program, underscoring that the positive survival signal comes from a partner-run trial in a region whose patient mix and trial design may affect global generalizability.
- Investor response was mixed and volatile after the data release, with contrasting reports of intraday price moves and Bernstein reiterating an underperform rating and a $7.70 target while citing concerns about non‑statistically significant trends in a separate Harmoni‑6 study.
- Regulatory and commercial outcomes will hinge on confirmatory analyses and broader data; if replicated, the result could change treatment options for patients in the studied setting but regulators will likely seek more global evidence before widening approvals.